Theorem Clinical Research Expands Leadership and Prepares for Growth
News Nov 13, 2014
Theorem Clinical Research has named Kathryn Bohannon as vice president of biopharmaceutical development and Angela Weston as vice president of business development in Europe and Asia.
Bohannon increases Theorem’s scientific and medical leadership in pediatrics and rare disease with almost 20 years of diverse pharmaceutical research and development experience, including Phase I-IV clinical research, laboratory research and development as well as U.S. and global project management and direct sales and marketing.
She has developed and managed projects across multiple therapeutic areas and clinical settings, including the Best Pharmaceuticals for Children Act - Data Coordinating Center within the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Weston brings more than 20 years of experience to Theorem, spanning a broad range of commercial disciplines in the pharmaceutical, biotech and medical device industries. She has worked extensively in business development, previously serving as senior vice president for business development at a global clinical contract research organization.
In this role, she organized and managed the pharmaceutical, medical device and clinical resource sales teams. Additionally, Weston is a clinical nurse specialist and paramedic.
“These professionals further enhance our capabilities and client services,” said John Potthoff, Theorem president and CEO. “We have the right experts in place to provide meaningful expertise in key aspects of clinical trials.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018